Today, the pipeline for Parkinson's treatments is robust with at least 51 therapies that may slow or stop disease in clinical trials. Listen to Michael J. Fox Foundation (MJFF) scientist, Jamie Eberling, PhD; MJFF CEO Todd Sherer, PhD; and president and senior scientist at the Institute for Neurodegenerative Disorders, Ken Marek, MD, discuss trials around:
- Strategies against genetic targets such as alpha-synuclein, LRRK2, and GBA
- Repurposed therapies (developed for a different disease that are being tested in Parkinson's)
- Therapies against other pathways, including inflammation and oxidative stress
Want to see the slides and other resources from the webinar? Watch on demand.
Rather listen on-the-go? Subscribe to our Michael J. Fox Foundation Parkinson's Podcast on iTunes or through any podcast app on your smartphone or tablet.